Chronic obstructive pulmonary disease (COPD) is one of the leading non-cardiac contributors to early mortality in people with schizophrenia. The reason is straightforward — smoking rates in this population have historically been three to four times the general-population rate, cumulative exposure is high, and screening is poor. A 2018 systematic review in Schizophrenia Research found COPD prevalence in schizophrenia roughly double that of matched controls (Suetani et al., 2018).
COPD is twice as common in schizophrenia as in the general population, almost entirely because of high smoking rates — and it is one of the most preventable causes of premature death in this group.
Why smoking rates are so high
The CDC and NIMH both note that smoking prevalence in adults with serious mental illness has historically run between 50% and 70%, compared with around 12–14% in the general US adult population (CDC MMWR, 2019). Several reasons:
- Self-medication of negative and cognitive symptoms. Nicotine transiently improves attention, working memory, and sensory gating in people with schizophrenia. Many patients describe it as the only thing that "clears the static."
- Pharmacologic interaction. Smoking induces CYP1A2, lowering blood levels of olanzapine, clozapine, and several other antipsychotics. Quitting can substantially raise levels and side effects unless doses are adjusted.
- Social environment. Inpatient units, group homes, and clubhouses have historically been smoking-tolerant environments.
- Targeted marketing. Tobacco companies historically targeted people with mental illness with discounts and free samples.
- Lower cessation support. Clinicians have under-treated nicotine dependence in this population, partly out of misplaced concern that quitting would worsen psychiatric symptoms.
What COPD is
COPD is a progressive lung disease characterised by airflow limitation that is not fully reversible. The two main components are chronic bronchitis (inflammation and excess mucus in the airways) and emphysema (destruction of alveolar walls, reducing gas exchange). Symptoms include chronic cough, sputum, breathlessness on exertion, wheezing, and frequent chest infections. The GOLD report is the international standard reference.
How it is diagnosed
Diagnosis requires spirometry: a post-bronchodilator FEV1/FVC ratio less than 0.70 indicates persistent airflow limitation. Spirometry is widely available in primary care and is brief, cheap, and well tolerated. The biggest barrier is referral — clinicians often do not order it in people with serious mental illness even when symptoms suggest COPD.
What treatment looks like
Smoking cessation
The single intervention that changes the trajectory of COPD. Lung function decline slows substantially after quitting, and infections become less frequent. People with schizophrenia can quit smoking — multiple randomised trials, including the EAGLES trial published in The Lancet, found varenicline and bupropion to be effective and safe in this population (Anthenelli et al., 2016). See our quit-smoking strategies guide.
Bronchodilators
Inhaled long-acting bronchodilators (LAMA, LABA) are the foundation of symptomatic treatment. They improve exercise tolerance and reduce exacerbations.
Inhaled corticosteroids
Used in selected patients with frequent exacerbations or features of asthma overlap.
Vaccinations
Annual influenza, pneumococcal, COVID-19, and (for older adults) RSV vaccines reduce exacerbations and pneumonia hospitalisations.
Pulmonary rehabilitation
A structured program of exercise, education, and breathing techniques — substantially improves quality of life and exercise capacity.
Oxygen therapy
For severe COPD with chronic hypoxemia, long-term home oxygen is the only treatment shown to reduce mortality.
You experience worsening breathlessness, increased sputum volume or change in colour (yellow or green), fever, chest pain, or confusion — these can be signs of a COPD exacerbation or pneumonia and may require antibiotics, steroids, or hospital care.
The smoking-cessation/antipsychotic interaction
This deserves its own paragraph because it surprises many patients and clinicians. Tobacco smoke induces the liver enzyme CYP1A2, which metabolises clozapine, olanzapine, asenapine, and several other antipsychotics. When a long-time smoker stops smoking, blood levels of these drugs can rise by 50% or more over a few weeks, sometimes producing intolerable sedation or even toxicity. The Clozapine FDA label explicitly warns about this. The fix is straightforward — anticipate it and reduce the dose proactively, or check a level — but it requires coordination between primary care and psychiatry.
What the system needs to do
- Smoking status documented at every psychiatric visit, and cessation offered at every encounter.
- Spirometry available in mental-health clinics or routinely referred to primary care.
- Routine vaccinations integrated into psychiatric care.
- Pharmacist review when smoking status changes, to adjust doses.
The big picture
COPD is one of the most preventable causes of death in schizophrenia. Quitting smoking before age 40 returns much of the lost life expectancy from smoking. Quitting at any age slows COPD progression. The barriers are real — biological dependence, cognitive symptoms, environment — but the tools work, and the data on treatment effectiveness in this population are now strong enough that under-treatment is no longer defensible.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.